Array reports Phase III OS data for encorafenib/binimetinib/Erbitux triple combo in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) reported additional data from the safety lead-in portion of the open-label, international Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a one-year overall survival (OS) rate of 62% in 29 evaluable BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients who progressed after one or two prior lines of therapy. Median OS was not reached through 12.6 months. Data were presented at the World Congress on Gastrointestinal Cancer in Barcelona.

The company has previously reported response data from the trial (see "Array Reports Updated Data For Encorafenib/Binimetinib/Erbitux in Metastatic CRC")...